Zoledronic acid and clinical fractures and mortality after hip fracture.

By K. Lyles, Cathleen Colón-Emeric, J. Magaziner, J. Adachi, C. Pieper, C. Mautalen, L. Hyldstrup, C. Recknor, L. Nordsletten, K. A. Moore and 9 more. New England Journal of Medicine, 2007

1,826 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/f4dd952929206bad6d80b596c1f0a33f8f041455

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Orthopedics and Sports Medicine

In Surgery

Citations in the corpus

Excess mortality following hip fracture: a systematic epidemiological review (2009, background): “Encouragingly, recent studies have indicated that pharmacologic treatment for osteoporosis may decrease the risk of subsequent hip fractures [91] and potentially also the increased risk of death [ 92 ].”
Bone regenerative medicine: classic options, novel strategies, and future directions (2014, background): “It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases and fractures [126].”
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, background): “A further trial with once yearly IV zoledronate in patients after hip fracture showed that prevention of further nonvertebral fractures could be significantly reduced [136].”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “decrease the risk of fracture and mortality when given shortly after a first hip fracture [225].”
Bisphosphonates: the first 40 years. (2011, background): “observations indicates that bisphosphonates may prevent various cancers and also reduce mortality and increase life span [221–236].”
Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014, background): “Zoledronic acid is also indicated for the prevention of new clinical fractures in patients (both women and men) who have recently had a lowtrauma (osteoporosis-related) hip fracture [58].”
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group (2014, methodology): “In several studies, vertebral fractures were a part of the entry criteria [17–19], with average T-scores reflecting osteopenia in many cases, and in other cases, FRAX data were applied post hoc to determine the efficacy based upon baseline FRAX scores [20, 21].”
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus (2015, neutral): “BPs for the treatment of ONJ ranges from 0 to 90 per 100,000 patient-years.((58,59,65,67,68)) Last, the incidence of ONJ in patients who are prescribed Dmab ranges from 0 to 30.”
Medication-Related Osteonecrosis of the Jaw—2014 Update (2014, background): “9 years((58)); the Glucocorticoid-InducedOsteoporosis Trial involved 833 subjects and compared zoledronic acid 5mg or risedronate 5mg over 1 year((76)); the Male Osteoporosis Trial involved 302 subjects”